78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
The GLP-1 industry is accelerating growth as adoption rates continue to rise, and these three pharmaceuticals companies could be positioned to capitalize.
SAN DIEGO , March 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic...
The S&P 500 Index ($SPX ) (SPY ) on Thursday closed down -1.57%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -1.34%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -2.04%. March...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.52%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.07%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.08%. March E-mini S&P futures...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.20%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.32%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.10%. March E-mini S&P futures (ESH26...
Conference call scheduled for 4:30 p.m. ET today
Conference Call Scheduled for Wednesday, February 11 at 4:30 p.m. Eastern Time
These growth stocks have the potential to dramatically outperform if you are willing to bear the risks.
These three biotech stocks combine scale, late-stage pipelines, and analyst confidence, giving investors compelling upside potential in 2026